title: Transfusion-related adverse events in the Platelet Dose study.
abstract: BACKGROUND
  How platelet (PLT) product characteristics such as dose, source (whole blood derived [WBD] vs. apheresis), storage duration, and ABO matching status affect the risks of transfusion-related adverse events (TRAEs) is unclear. Similarly, more information is needed to define how recipient characteristics affect the frequency of TRAEs after PLT transfusion.
  
  
  METHODS
  In the multicenter Platelet Dose ("PLADO") study, pediatric and adult hematology-oncology patients with hypoproliferative thrombocytopenia were randomized to receive low-dose (LD), medium-dose (MD), or high-dose (HD) PLT prophylaxis for a pretransfusion PLT count of not more than 10 × 10(9) /L. All PLT units (apheresis or WBD) were leukoreduced. Post hoc analyses of PLADO data were performed using multipredictor models.
  
  
  RESULTS
  A total of 5034 PLT transfusions to 1102 patients were analyzed. A TRAE occurred with 501 PLT transfusions (10.0%). The most common TRAEs were fever (6.6% of transfusions), allergic or hypersensitivity reactions (1.9%), and sinus tachycardia (1.8%). Patients assigned HD PLTs were more likely than LD or MD patients to experience any TRAE (odds ratio for HD vs. MD, 1.50; 95% confidence interval, 1.10-2.05; three-group comparison p = 0.02). PLT source and ABO matching status were not significantly related to overall TRAE risk. Compared to a patient's first PLT transfusion, subsequent PLT transfusions were less likely to have a TRAE reported, primarily due to a lower risk of allergic or hypersensitivity reactions.
  
  
  CONCLUSIONS
  The most important PLT unit characteristic associated with TRAEs was PLT dose per transfusion. HD PLTs may increase the risk of TRAEs, and LD PLTs may reduce the risk.
authors: Brigham and Women's Hospital, Boston, Massachusetts.
authors: Richard M
authors: RM
authors: Kaufman
authors: Susan F
authors: SF
authors: Assmann
authors: Darrell J
authors: DJ
authors: Triulzi
authors: Ronald G
authors: RG
authors: Strauss
authors: Paul
authors: P
authors: Ness
authors: Suzanne
authors: S
authors: Granger
authors: Sherrill J
authors: SJ
authors: Slichter
mesh_terms: D000017:ABO Blood-Group System; D000293:Adolescent; D000328:Adult; D000368:Aged; D001787:Blood Group Incompatibility / Q000276:immunology; D002648:Child; D002675:Child, Preschool; D004306:Dose-Response Relationship, Immunologic; D005334:Fever / Q000453:epidemiology / Q000209:etiology; D006402:Hematologic Diseases / Q000276:immunology / Q000628:therapy; D006470:Hemorrhage / Q000517:prevention & control; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D047589:Leukocyte Reduction Procedures; D008875:Middle Aged; D018448:Models, Immunological; D009369:Neoplasms / Q000276:immunology / Q000628:therapy; D010976:Platelet Count; D017713:Platelet Transfusion / Q000009:adverse effects*; D010983:Plateletpheresis; D013616:Tachycardia, Sinus / Q000453:epidemiology / Q000209:etiology; D013921:Thrombocytopenia / Q000628:therapy; D065227:Transfusion Reaction / Q000453:epidemiology / Q000209:etiology*; D055815:Young Adult
chemical_list: D000017:ABO Blood-Group System